Business Segments Marker Therapeutics, Inc.
Equities
MRKR
US57055L2060
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.370 USD | -2.84% |
|
0.00% | -8.05% |
| 11-14 | Marker Therapeutics Q3 net loss narrows to $2 mln | RE |
| 11-13 | Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
The Discovery, Development, and Commercialization of its Product Candidates | 467K | 1.24M | 9.01M | 3.31M | 6.59M | |||||
Total Assets | 45.61M | 68.14M | 34.42M | 17.13M | 22.02M | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | 3.68K | 49.95K | |||||
CAPEX | -10.43M | -3.13M | -4.95M | - | - | |||||
EBT | -28.71M | -41.88M | -29.93M | -14.04M | -10.68M | |||||
D&A | 1.08M | 3.16M | 3.68M | - | - | |||||
Operating Income | -28.89M | -39.48M | -29.95M | -14.58M | -11.12M | |||||
Net Income | -28.71M | -41.88M | -29.93M | -8.24M | -10.73M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 467K | 1.24M | 9.01M | 3.31M | 6.59M | |||||
Total Assets | 45.61M | 68.14M | 34.42M | 17.13M | 22.02M | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | 3.68K | 49.95K | |||||
D&A | 1.08M | 3.16M | 3.68M | - | - | |||||
CAPEX | -10.43M | -3.13M | -4.95M | - | - | |||||
Net Income | -28.71M | -41.88M | -29.93M | -8.24M | -10.73M | |||||
EBT | -28.71M | -41.88M | -29.93M | -14.04M | -10.68M | |||||
Operating Income | -28.89M | -39.48M | -29.95M | -14.58M | -11.12M |
- Stock Market
- Equities
- MRKR Stock
- Financials Marker Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition